Our findings support the development of targeting strategies that include novel combinatorial approaches with PI3K interruption and potential USP11 and/or eIF4B inhibitors that may have broad utility in controlling DLBCL and related malignancies. Here, USP11 is linked to diffuse large B-cell lymphoma.